vs

Side-by-side financial comparison of NEUROCRINE BIOSCIENCES INC (NBIX) and Qnity Electronics, Inc. (Q). Click either name above to swap in a different company.

Qnity Electronics, Inc. is the larger business by last-quarter revenue ($1.3B vs $805.5M, roughly 1.6× NEUROCRINE BIOSCIENCES INC). NEUROCRINE BIOSCIENCES INC runs the higher net margin — 19.1% vs 16.5%, a 2.5% gap on every dollar of revenue. On growth, NEUROCRINE BIOSCIENCES INC posted the faster year-over-year revenue change (28.3% vs 11.1%). Qnity Electronics, Inc. produced more free cash flow last quarter ($568.0M vs $386.0M).

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

NBIX vs Q — Head-to-Head

Bigger by revenue
Q
Q
1.6× larger
Q
$1.3B
$805.5M
NBIX
Growing faster (revenue YoY)
NBIX
NBIX
+17.2% gap
NBIX
28.3%
11.1%
Q
Higher net margin
NBIX
NBIX
2.5% more per $
NBIX
19.1%
16.5%
Q
More free cash flow
Q
Q
$182.0M more FCF
Q
$568.0M
$386.0M
NBIX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
NBIX
NBIX
Q
Q
Revenue
$805.5M
$1.3B
Net Profit
$153.7M
$211.0M
Gross Margin
97.8%
45.1%
Operating Margin
26.2%
21.3%
Net Margin
19.1%
16.5%
Revenue YoY
28.3%
11.1%
Net Profit YoY
49.1%
6.0%
EPS (diluted)
$1.49
$1.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NBIX
NBIX
Q
Q
Q4 25
$805.5M
Q3 25
$794.9M
$1.3B
Q2 25
$687.5M
Q1 25
$572.6M
Q4 24
$627.7M
Q3 24
$622.1M
$1.1B
Q2 24
$590.2M
Q1 24
$515.3M
Net Profit
NBIX
NBIX
Q
Q
Q4 25
$153.7M
Q3 25
$209.5M
$211.0M
Q2 25
$107.5M
Q1 25
$7.9M
Q4 24
$103.1M
Q3 24
$129.8M
$199.0M
Q2 24
$65.0M
Q1 24
$43.4M
Gross Margin
NBIX
NBIX
Q
Q
Q4 25
97.8%
Q3 25
98.2%
45.1%
Q2 25
98.4%
Q1 25
98.4%
Q4 24
98.5%
Q3 24
98.7%
47.0%
Q2 24
98.4%
Q1 24
98.5%
Operating Margin
NBIX
NBIX
Q
Q
Q4 25
26.2%
Q3 25
30.1%
21.3%
Q2 25
21.2%
Q1 25
4.1%
Q4 24
22.6%
Q3 24
29.5%
21.8%
Q2 24
24.6%
Q1 24
19.3%
Net Margin
NBIX
NBIX
Q
Q
Q4 25
19.1%
Q3 25
26.4%
16.5%
Q2 25
15.6%
Q1 25
1.4%
Q4 24
16.4%
Q3 24
20.9%
17.3%
Q2 24
11.0%
Q1 24
8.4%
EPS (diluted)
NBIX
NBIX
Q
Q
Q4 25
$1.49
Q3 25
$2.04
$1.01
Q2 25
$1.06
Q1 25
$0.08
Q4 24
$1.00
Q3 24
$1.24
$0.95
Q2 24
$0.63
Q1 24
$0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NBIX
NBIX
Q
Q
Cash + ST InvestmentsLiquidity on hand
$713.0M
$128.0M
Total DebtLower is stronger
$1.7B
Stockholders' EquityBook value
$3.3B
$9.1B
Total Assets
$4.6B
$12.5B
Debt / EquityLower = less leverage
0.19×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NBIX
NBIX
Q
Q
Q4 25
$713.0M
Q3 25
$340.2M
$128.0M
Q2 25
$264.0M
Q1 25
$194.1M
Q4 24
$233.0M
Q3 24
$349.1M
Q2 24
$139.7M
Q1 24
$396.3M
Total Debt
NBIX
NBIX
Q
Q
Q4 25
Q3 25
$1.7B
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
NBIX
NBIX
Q
Q
Q4 25
$3.3B
Q3 25
$3.0B
$9.1B
Q2 25
$2.7B
Q1 25
$2.5B
Q4 24
$2.6B
Q3 24
$2.7B
$11.1B
Q2 24
$2.5B
Q1 24
$2.4B
Total Assets
NBIX
NBIX
Q
Q
Q4 25
$4.6B
Q3 25
$4.3B
$12.5B
Q2 25
$3.9B
Q1 25
$3.7B
Q4 24
$3.7B
Q3 24
$3.5B
Q2 24
$3.3B
Q1 24
$3.5B
Debt / Equity
NBIX
NBIX
Q
Q
Q4 25
Q3 25
0.19×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NBIX
NBIX
Q
Q
Operating Cash FlowLast quarter
$388.4M
$782.0M
Free Cash FlowOCF − Capex
$386.0M
$568.0M
FCF MarginFCF / Revenue
47.9%
44.5%
Capex IntensityCapex / Revenue
0.3%
16.8%
Cash ConversionOCF / Net Profit
2.53×
3.71×
TTM Free Cash FlowTrailing 4 quarters
$743.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NBIX
NBIX
Q
Q
Q4 25
$388.4M
Q3 25
$227.5M
$782.0M
Q2 25
$102.0M
Q1 25
$64.8M
Q4 24
$242.5M
Q3 24
$158.0M
Q2 24
$64.6M
Q1 24
$130.3M
Free Cash Flow
NBIX
NBIX
Q
Q
Q4 25
$386.0M
Q3 25
$214.3M
$568.0M
Q2 25
$89.5M
Q1 25
$54.1M
Q4 24
$235.2M
Q3 24
$149.9M
Q2 24
$53.0M
Q1 24
$119.1M
FCF Margin
NBIX
NBIX
Q
Q
Q4 25
47.9%
Q3 25
27.0%
44.5%
Q2 25
13.0%
Q1 25
9.4%
Q4 24
37.5%
Q3 24
24.1%
Q2 24
9.0%
Q1 24
23.1%
Capex Intensity
NBIX
NBIX
Q
Q
Q4 25
0.3%
Q3 25
1.7%
16.8%
Q2 25
1.8%
Q1 25
1.9%
Q4 24
1.2%
Q3 24
1.3%
Q2 24
2.0%
Q1 24
2.2%
Cash Conversion
NBIX
NBIX
Q
Q
Q4 25
2.53×
Q3 25
1.09×
3.71×
Q2 25
0.95×
Q1 25
8.20×
Q4 24
2.35×
Q3 24
1.22×
Q2 24
0.99×
Q1 24
3.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NBIX
NBIX

INGREZZA Net Product Sales$653.8M81%
CRENESSITY Net Product Sales$135.4M17%
Other Income$12.6M2%
Collaboration Revenue$7.2M1%

Q
Q

Semiconductor Technologies$693.0M54%
Interconnect Solutions$583.0M46%

Related Comparisons